BCRB 2018

19/09/2018

EGFR inhibition + RCT in HNSCC

• Other EGFR inhibitors ? CONCERT trials • CONCERT-1

• Open-label RCT phase II trial, stage III and IV HNSCC • RCT (n=63) vs R C T + Panitumumab (n=87) • CONCERT-2 • Open-label RCT phase II trial, stage III and IV HNSCC • RCT (n= 61) vs RT + Panitumumab (n=90)

EGFR inhibition + RCT in HNSCC

• Other EGFR inhibitors ? CONCERT trials

CONCERT-1: addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit

CONCERT-2: panitumumab cannot replace cisplatin in combined treatment with RT

12